RICHMOND HILL, Ontario, Sept. 03, 2019 — Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that they, together with Moffitt Cancer Center (“Moffitt”), will be presenting a poster entitled “Pharmacodynamics of targeted urease and checkpoint blockade using Chemical Exchange Saturation Transfer (“CEST”) and 31P-magnetic resonance spectroscopy (“31P-MRS”).” The question asked, “Is there a role for hyperpolarized 13C and 15N?”
The poster presentation will take place at the World Molecular Imaging Congress (“WMIC”), which is taking place at the Palais des congrès de Montréal in Montréal, Quebec, Canada (http://www.wmis.org/2019-wmic/) on September 4th through the 7th, 2019.